Latest News and Press Releases

Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET

Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture.

Castle Biosciences will release Q2 2025 financial results and host conference call on Monday, Aug. 4, 2025 at 4:30 p.m. ET

FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on...

Castle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB.

Derek Maetzold, CEO of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during BIO 2025.

Castle Biosciences' Founder and CEO Derek Maetzold Honored with Lifetime Achievement Award by The American Business Awards

Castle will present new data aimed at enhancing the clinical management of patients with cutaneous melanoma and uveal melanoma at ASCO 2025.